Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Hookipa Pharma Inc (HOOK)
NASDAQ:HOOK
Hookipa Pharma (HOOK) Stock Price & Analysis
459 Followers
HOOK Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.41 - $2.05
Previous Close$0.76
Volume172.84K
Average Volume (3M)543.45K
Market Cap
$75.69M
Enterprise Value-$55.62M
Total Cash (Recent Filing)$135.59M
Total Debt (Recent Filing)$4.28M
Price to Earnings (P/E)-0.8
Beta0.89
Next Earnings
May 15, 2024EPS Estimate
-$0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.91
Shares Outstanding98,950,107
10 Day Avg. Volume645,566
30 Day Avg. Volume543,450
Standard Deviation0.22
R-Squared0.06
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)0.89
Price to Sales (P/S)9.40
Price to Cash Flow (P/CF)-1.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-3.50
Enterprise Value/Gross Profit-3.90
Enterprise Value/Ebitda0.83
Forecast
1Y Price Target
$5.13Price Target Upside570.68% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Hookipa Pharma News
Bulls Say, Bears Say
Bulls Say
Clinical Trial UpdatesUpcoming Phase 2 data for HB-200 in combination with pembrolizumab could demonstrate sustained response rates in HPV+ head and neck cancer.
Financial HealthHookipa's reported total revenues and cash reserves are set to fund operations well into the future, indicating financial stability.
Strategic FocusHookipa's strategic focus on HPV+ cancers and partnerships in infectious diseases underscores its commitment to advancing its pipeline.
Bears Say
Analyst SentimentAnalyst's recommendation for Hookipa Pharma's stock price target was lowered from $7 to $5.
Corporate PartnershipRoche terminated the HB-700 and HB-800 collaboration and licensing agreement.
Regulatory RiskHOOK faces a delisting risk if the stock price does not stay above $1.00 for a required number of consecutive business days, making upcoming trial updates critical.
---
Ownership Overview
8.06% Insiders
6.66% Mutual Funds
2.39% Other Institutional Investors
82.88% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
HOOK FAQ
What was Hookipa Pharma Inc’s price range in the past 12 months?
Hookipa Pharma Inc lowest stock price was $0.41 and its highest was $2.05 in the past 12 months.
What is Hookipa Pharma Inc’s market cap?
Currently, no data Available
When is Hookipa Pharma Inc’s upcoming earnings report date?
Hookipa Pharma Inc’s upcoming earnings report date is May 15, 2024 which is in 20 days.
How were Hookipa Pharma Inc’s earnings last quarter?
Hookipa Pharma Inc released its earnings results on Mar 22, 2024. The company reported -$0.22 earnings per share for the quarter, missing the consensus estimate of -$0.192 by -$0.028.
Is Hookipa Pharma Inc overvalued?
According to Wall Street analysts Hookipa Pharma Inc’s price is currently Undervalued.
Does Hookipa Pharma Inc pay dividends?
Hookipa Pharma Inc does not currently pay dividends.
What is Hookipa Pharma Inc’s EPS estimate?
Hookipa Pharma Inc’s EPS estimate is -$0.1.
How many shares outstanding does Hookipa Pharma Inc have?
Hookipa Pharma Inc has 96,550,590 shares outstanding.
What happened to Hookipa Pharma Inc’s price movement after its last earnings report?
Hookipa Pharma Inc reported an EPS of -$0.22 in its last earnings report, missing expectations of -$0.192. Following the earnings report the stock price went down -1.389%.
Which hedge fund is a major shareholder of Hookipa Pharma Inc?
Among the largest hedge funds holding Hookipa Pharma Inc’s share is Baker Bros Advisors LP. It holds Hookipa Pharma Inc’s shares valued at 7M.
---
Hookipa Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.13 (570.68% Upside)
$5.13 (570.68% Upside)
Hedge Fund Trend
Increased
By 62.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.0%
Last 30 Days ▼ 1.3%
Last 30 Days ▼ 1.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
1.73%
12-Months-Change
Fundamentals
Return on Equity
-84.81%
Trailing 12-Months
Asset Growth
-5.35%
Trailing 12-Months
Company Description
Hookipa Pharma Inc
HOOKIPA Pharma, Inc. engages in the development of immunotherapeutics, targeting infectious diseases and cancers based on its proprietary its arenavirus platform that is designed to reprogram the body's immune system. Its product include VaxWace, a replication-deficient viral vector; and TheraT, a replication-attenuated viral vector, are designed to induce robust antigen specific CD8+ T cells and pathogen-neutralizing antibodies. The company was founded by Rolf Zinkernagel, Andreas Bergthaler, Lukas Flatz, and Daniel Pinschewer in 2011 and is headquartered in New York, NY.
---
HOOK Company Deck
---
HOOK Earnings Call
Q4 2023
0:00 / 0:00
---
HOOK Stock 12 Months Forecast
Average Price Target
$5.13
▲(570.68% Upside)
Technical Analysis
Best Analysts Covering HOOK
1 Year
1 Year Success Rate
8/25 ratings generated profit
1 Year Average Return
-27.21%
assigned a buy rating last month
Copying Brian Abrahams's trades and holding each position for 1 Year would result in 32.00% of your transactions generating a profit, with an average return of -27.21% per trade.
---